Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;16(6):497-516.
doi: 10.2217/nnm-2020-0441. Epub 2021 Mar 8.

Nanotechnology against the novel coronavirus (severe acute respiratory syndrome coronavirus 2): diagnosis, treatment, therapy and future perspectives

Hamid Rashidzadeh  1   2 , Hossein Danafar  2   3 , Hossein Rahimi  2 , Faezeh Mozafari  2 , Marziyeh Salehiabar  4 , Mohammad Amin Rahmati  2 , Samaneh Rahamooz-Haghighi  5 , Navid Mousazadeh  2 , Ali Mohammadi  2 , Yavuz Nuri Ertas  6   7 , Ali Ramazani  1 , Irada Huseynova  8 , Rovshan Khalilov  3   9   10 , Soodabeh Davaran  3   4 , Thomas J Webster  11 , Taras Kavetskyy  3   12   13 , Aziz Eftekhari  14   12   10   15 , Hamed Nosrati  2   3 , Mehdi Mirsaeidi  16
Affiliations
Review

Nanotechnology against the novel coronavirus (severe acute respiratory syndrome coronavirus 2): diagnosis, treatment, therapy and future perspectives

Hamid Rashidzadeh et al. Nanomedicine (Lond). 2021 Mar.

Abstract

COVID-19, as an emerging infectious disease, has caused significant mortality and morbidity along with socioeconomic impact. No effective treatment or vaccine has been approved yet for this pandemic disease. Cutting-edge tools, especially nanotechnology, should be strongly considered to tackle this virus. This review aims to propose several strategies to design and fabricate effective diagnostic and therapeutic agents against COVID-19 by the aid of nanotechnology. Polymeric, inorganic self-assembling materials and peptide-based nanoparticles are promising tools for battling COVID-19 as well as its rapid diagnosis. This review summarizes all of the exciting advances nanomaterials are making toward COVID-19 prevention, diagnosis and therapy.

Keywords: COVID-19; SARS-CoV-2; coronavirus; diagnosis; nanotechnology; treatment.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Structure of severe acute respiratory syndrome coronavirus 2.
Reproduced with permission from [17] © American Chemical Society (2021).
Figure 2.
Figure 2.. Nanostructured materials in battling coronavirus 2019 and the rapid diagnosis of coronavirus 2019.
Figure 3.
Figure 3.. Schematic illustration of polymeric virus catchers fabricated using molecular imprinting techniques.
Reproduced with permission from [65] licensed with CC BY 3.0.
Figure 4.
Figure 4.. Hollow nanoparticles against coronavirus disease-19.
(A) Fabrication of a nanovaccine based on synthetic biodegradable PLGA and DEPE-PEG polymers using a double emulsion technique. (B, C) Cryo-electron microscopy of cdGMP-loaded hollow nanoparticles. (D) Determination of the size distribution of nanoparticles via dynamic light scattering. HPLC diagram of adjuvant-loaded nanoparticles (NP[cdGMP]) and soluble cdGMP. (E) HPLC diagram of soluble cdGMP and adjuvant-loaded nanoparticles (NP[cdGMP]). (F) Calibration curve for the determination of cdGMP encapsulation efficiency. (G) cdGMP release profiles at pH 5 and pH 7. PLGA: Poly (lactic-co-glycolic acid). Reproduced with permission from [66] © WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim (2019).
Figure 5.
Figure 5.. Inactivation of influenza A virus treated with porous gold nanoparticles.
PoGNP interacts with Influenza A virus surface proteins and cleaves their disulfide bonds. Inactivated viruses exhibit lower infectivity to cells. PoGNP: Porous gold nanoparticle. Reproduced with permission from [96] licensed with CC BY 4.0.
Figure 6.
Figure 6.. Schematic representation of possible strategies to tackle coronavirus 2019 using nanotechnology.
See this image and copyright information in PMC

References

    1. Khan S, Liu J, Xue M. Transmission of SARS-CoV-2, required developments in research and associated public health concerns. Front. Med. 7, 310 (2020). - PMC - PubMed
    1. Valentini M, Zmerly H. Antirheumatic drugs for COVID-19 treatment based on the phases of the disease. J. Popul. Ther. Clin. Pharmacol. 27(Suppl. 1), e14–e25 (2020). - PubMed
    1. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 39(5), 529–539 (2017). - PMC - PubMed
    1. International Committee on Taxonomy of Viruses. Van Regenmortel MHV, Fauquet CM, Bishop DHL. Virus taxonomy: classification and nomenclature of viruses: Seventh report of the International Committee on Taxonomy of Viruses. Acadmeic Press, CA, USA, 395–480 (2000).
    1. Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol. Mol. Biol. Rev. 69(4), 635–664 (2005). - PMC - PubMed

Publication types

LinkOut - more resources